Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Core Viewpoint - Avadel Pharmaceuticals plc will host a conference call on May 7, 2025, to provide a corporate update and discuss its financial results for Q1 2025 [1]. Company Overview - Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines to improve patients' lives [3]. - The company’s commercial product, LUMRYZ™, is the first and only once-at-bedtime oxybate approved by the FDA for treating cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy [3]. Conference Call Details - The conference call will take place at 8:00 a.m. ET on May 7, 2025, and will be accessible via the investor relations section of the company's website [2]. - A replay of the webcast will be available for 90 days following the event [2].